BNP Paribas set a GBX 5,300 ($68.45) price objective on AstraZeneca plc (LON:AZN) in a research report released on Monday. The brokerage currently has a neutral rating on the biopharmaceutical company’s stock.

Several other analysts have also issued reports on AZN. Deutsche Bank AG boosted their price target on AstraZeneca plc from GBX 5,350 ($69.09) to GBX 5,700 ($73.61) and gave the company a buy rating in a report on Monday, May 15th. HSBC Holdings plc reissued a reduce rating and set a GBX 4,200 ($54.24) price target on shares of AstraZeneca plc in a report on Monday, May 15th. Shore Capital raised AstraZeneca plc to a hold rating and set a GBX 4,800 ($61.99) price target for the company in a report on Tuesday, May 16th. Berenberg Bank boosted their price target on AstraZeneca plc from GBX 5,670 ($73.23) to GBX 5,850 ($75.55) and gave the company a buy rating in a report on Wednesday, May 17th. Finally, Jefferies Group LLC set a GBX 4,700 ($60.70) price target on AstraZeneca plc and gave the company a neutral rating in a report on Saturday, May 20th. Three equities research analysts have rated the stock with a sell rating, nine have given a hold rating and ten have given a buy rating to the company’s stock. AstraZeneca plc presently has a consensus rating of Hold and a consensus price target of GBX 4,963.82 ($64.11).

Shares of AstraZeneca plc (LON:AZN) opened at 4893.50 on Monday. The stock’s market cap is GBX 61.95 billion. AstraZeneca plc has a one year low of GBX 3,996.00 and a one year high of GBX 5,520.00. The company’s 50-day moving average price is GBX 4,571.40 and its 200-day moving average price is GBX 4,878.32.

AstraZeneca plc (LON:AZN) last released its quarterly earnings results on Wednesday, July 26th. The biopharmaceutical company reported $1.86 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.85 by $1.01. AstraZeneca plc had a return on equity of 14.36% and a net margin of 8.83%. Equities research analysts anticipate that AstraZeneca plc will post $3.75 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: This piece of content was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece of content on another domain, it was stolen and republished in violation of U.S. & international trademark and copyright legislation. The original version of this piece of content can be accessed at

The business also recently disclosed a dividend, which was paid on Monday, September 11th. Shareholders of record on Thursday, August 10th were given a dividend of GBX 68.90 ($0.89) per share. The ex-dividend date of this dividend was Thursday, August 10th. This represents a yield of 1.35%.

In related news, insider Nazneen Rahman acquired 39 shares of the firm’s stock in a transaction on Thursday, July 27th. The shares were acquired at an average cost of GBX 4,370 ($56.44) per share, for a total transaction of £1,704.30 ($2,201.08).

AstraZeneca plc Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Analyst Recommendations for AstraZeneca plc (LON:AZN)

Receive News & Stock Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related stocks with our FREE daily email newsletter.